Big COVID-19-Related Sales Drive Lilly’s Strong Q4 Performance
Executive Summary
Neutralizing antibody bamlanivimab brought in $871m during the fourth quarter, skewing already solid growth upwards. Discussion of donanemab in Alzheimer’s dominated Lilly’s quarterly call.
You may also be interested in...
Lilly COVID-19 Neutralizing Antibody Combo’s Reduced Infusion Time Offers Advantages For Providers
US FDA's EUA allows lower doses of the two antibodies than were tested in BLAZE-1, which should extend current supply. With Amgen, Lilly hopes to manufacture 1 million doses by mid-year.
Lilly Oncology President Anne White On Loxo Success, What’s To Come
White said the late 2019 creation of Loxo Oncology at Lilly to spearhead cancer R&D has exceeded her expectations. The executive also discussed COVID-19’s impact on drug sales and cancer screening.
Aducanumab Approval Decision Delayed: Could This Be Good News?
Even analysts who still doubt the FDA will approve the anti-amyloid antibody as the first disease-modifying Alzheimer’s treatment said aducanumab’s likelihood of approval has improved.